Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21098927> ?p ?o }
Showing triples 1 to 70 of
70
with 100 triples per page.
- Q21098927 subject Q7336348.
- Q21098927 subject Q8501361.
- Q21098927 subject Q8522216.
- Q21098927 abstract "Examorelin (INN) (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici. It is a hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 which was derived from GHRP-6 (which, in turn, is an analogue of ghrelin).Examorelin substantially and dose-dependently increases plasma levels of growth hormone (GH) in animals and humans. In addition, similarly to pralmorelin (GHRP-2) and GHRP-6, it slightly and dose-dependently stimulates the release of prolactin, adrenocorticotropic hormone (ACTH), and cortisol in humans. There are conflicting reports on the ability of examorelin to elevate insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 1 (IGFBP-1) levels in humans, with some studies finding no increase and others finding a slight yet statistically significant increase. Examorelin does not affect plasma levels of glucose, luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH) in humans.Examorelin releases more GH than does growth hormone-releasing hormone (GHRH) in humans, and produces synergistic effects on GH release in combination with GHRH, resulting in "massive" increases in plasma GH levels even with only low doses of examorelin. Pre-administration of GH blunts the GH-releasing effect of examorelin, while, in contrast, fully abolishing the effect of GHRH. Pre-treatment with IGF-1 also blunts the GH-elevating effect of examorelin. Testosterone, testosterone enanthate, and ethinyl estradiol, though not oxandrolone, have been found to significantly potentiate the GH-releasing effects of examorelin in humans. In accordance, likely due to increases in sex steroid levels, puberty has also been found to significantly augment the GH-elevating actions of examorelin in humans.A partial and reversible tolerance to the GH-releasing effects of examorelin occurs in humans with long-term administration (50–75% decrease in efficacy over the course of weeks to months).Examorelin reached phase II clinical trials for the treatment of growth hormone deficiency and congestive heart failure but did not complete development and was never marketed.".
- Q21098927 atcPrefix "None".
- Q21098927 casNumber "140703-51-1".
- Q21098927 iupacName "(2S)-6-amino-2-(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide".
- Q21098927 pubchem "6918297".
- Q21098927 thumbnail Hexarelin_structure.png?width=300.
- Q21098927 wikiPageWikiLink Q101065.
- Q21098927 wikiPageWikiLink Q1318776.
- Q21098927 wikiPageWikiLink Q14863714.
- Q21098927 wikiPageWikiLink Q14914301.
- Q21098927 wikiPageWikiLink Q15624037.
- Q21098927 wikiPageWikiLink Q172847.
- Q21098927 wikiPageWikiLink Q174211.
- Q21098927 wikiPageWikiLink Q18027673.
- Q21098927 wikiPageWikiLink Q181754.
- Q21098927 wikiPageWikiLink Q185690.
- Q21098927 wikiPageWikiLink Q190199.
- Q21098927 wikiPageWikiLink Q190875.
- Q21098927 wikiPageWikiLink Q200774.
- Q21098927 wikiPageWikiLink Q2035485.
- Q21098927 wikiPageWikiLink Q2066956.
- Q21098927 wikiPageWikiLink Q20707542.
- Q21098927 wikiPageWikiLink Q20707766.
- Q21098927 wikiPageWikiLink Q20707829.
- Q21098927 wikiPageWikiLink Q208360.
- Q21098927 wikiPageWikiLink Q21098924.
- Q21098927 wikiPageWikiLink Q21098925.
- Q21098927 wikiPageWikiLink Q211544.
- Q21098927 wikiPageWikiLink Q21163349.
- Q21098927 wikiPageWikiLink Q21163357.
- Q21098927 wikiPageWikiLink Q285166.
- Q21098927 wikiPageWikiLink Q30612.
- Q21098927 wikiPageWikiLink Q3153701.
- Q21098927 wikiPageWikiLink Q369262.
- Q21098927 wikiPageWikiLink Q37525.
- Q21098927 wikiPageWikiLink Q389934.
- Q21098927 wikiPageWikiLink Q409489.
- Q21098927 wikiPageWikiLink Q415563.
- Q21098927 wikiPageWikiLink Q420859.
- Q21098927 wikiPageWikiLink Q422812.
- Q21098927 wikiPageWikiLink Q425105.
- Q21098927 wikiPageWikiLink Q47273.
- Q21098927 wikiPageWikiLink Q485014.
- Q21098927 wikiPageWikiLink Q5036299.
- Q21098927 wikiPageWikiLink Q5611751.
- Q21098927 wikiPageWikiLink Q5984942.
- Q21098927 wikiPageWikiLink Q640448.
- Q21098927 wikiPageWikiLink Q7180990.
- Q21098927 wikiPageWikiLink Q7336348.
- Q21098927 wikiPageWikiLink Q7391026.
- Q21098927 wikiPageWikiLink Q7673066.
- Q21098927 wikiPageWikiLink Q79749.
- Q21098927 wikiPageWikiLink Q824258.
- Q21098927 wikiPageWikiLink Q8501361.
- Q21098927 wikiPageWikiLink Q8522216.
- Q21098927 atcPrefix "None".
- Q21098927 casNumber "140703".
- Q21098927 iupacName "-6".
- Q21098927 pubchem "6918297".
- Q21098927 type ChemicalSubstance.
- Q21098927 type Drug.
- Q21098927 type ChemicalObject.
- Q21098927 type Thing.
- Q21098927 type Q8386.
- Q21098927 comment "Examorelin (INN) (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici.".
- Q21098927 label "Examorelin".
- Q21098927 depiction Hexarelin_structure.png.